The effect of Roux-en-Y Gastric Bypass surgery in morbidly obese patients on pharmacokinetic of lansoprazole

Phase 4

Recruiting

• Conditions: Morbidly Obesity; Roux-en-y Gastric bypass, Lansoprazole, Pharmacokinetics

• Registration Number: TCTR20220118001
• Lead Sponsor: Ratchadapisek Sompoch Endowment Fund Chulalongkorn university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-18
• Study Completion: 2022-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

The target population is obese patients admitted to Chulalongkorn Hospital which have indications for surgery according to National Institute of Health (NIH) guidelines that are BMI> 40 kg / m2 or BMI> 35 kg / m2 and also have associated diseases such as diabetes, hypertension, coronary heart disease, sleep apnea, age over 18 years old and associated with peptic ulcers.

Exclusion Criteria

Patients with exclusion criteria are patients who had previously undergone bariatric surgery, unable to swallow drugs, taking statins for the dyslipidemia treatment, and in patients who is allergic to lansoprazole and or taking drug interacted with lansoprazole: Acalabrutinib, Atazanavir, Cilostazol, Citalopram, Dacomitinib, Dasatinib, Erlotinib, Methotrexate, Nelfinavir, Neratinib, Pazopanib, Pexidartinib, Rilpivirine, Tacrolimus

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic of Lansoprazole 1 day before and 6 weeks after the surgery AUC of concentration of Lansoprazole in plasma, half-life, Cmax, Tmax

Secondary Outcome Measures

Name	Time	Method
The difference of CYP polymorphism 1 day before surgery Type of CYP